Cargando…
High- and Low-Dose Oral Delayed-Release Mesalamine in Children With Mild-to-Moderately Active Ulcerative Colitis
OBJECTIVE: The aim of the study was to assess the safety and efficacy of high- and low-dose oral, delayed-release mesalamine in a randomized, double-blind, active control study of children with mild-to-moderately active ulcerative colitis. METHODS: Patients ages 5 to 17 years, with a Pediatric Ulcer...
Autores principales: | Winter, Harland S., Krzeski, Piotr, Heyman, Melvin B., Ibarguen-Secchia, Eduardo, Iwanczak, Barbara, Kaczmarski, Maciej, Kierkus, Jaroslaw, Kolaček, Sanja, Osuntokun, Bankole, Quiros, J. Antonio, Shah, Manoj, Yacyshyn, Bruce, Dunnmon, Preston M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4255757/ https://www.ncbi.nlm.nih.gov/pubmed/25419597 http://dx.doi.org/10.1097/MPG.0000000000000530 |
Ejemplares similares
-
Mucosal concentrations of N‐acetyl‐5‐aminosalicylic acid related to endoscopic activity in ulcerative colitis patients with mesalamine
por: Fukuda, Tomohiro, et al.
Publicado: (2020) -
Safety and efficacy of multimatrix mesalamine in paediatric patients with mild-to-moderate ulcerative colitis: a phase 3, randomised, double-blind study
por: Croft, Nicholas Michael, et al.
Publicado: (2023) -
Genetic variants in cellular transport do not affect mesalamine response in ulcerative colitis
por: Moran, Christopher J., et al.
Publicado: (2018) -
Myocarditis Secondary to Mesalamine-Induced Cardiotoxicity in a Patient with Ulcerative Colitis
por: Okoro, Kelechukwu U., et al.
Publicado: (2018) -
The role of mesalamine in the treatment of ulcerative colitis
por: Karagozian, Raffi, et al.
Publicado: (2007)